Search Details

Word: ingelheim (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...increase in desire and a decrease in distress. When we look at this against a backdrop of a common and distressing problem that affects 1 of 10 women and for which no treatment exists, well, we are feeling very positive," said Michael Sand, director of clinical research for Boehringer Ingelheim, which originally developed the drug, flibanserin, in the 1990s as an antidepressant. (The drug proved not to work for depression...

Author: /time Magazine | Title: Female Sexual Dysfunction: Myth or Malady? | 11/18/2009 | See Source »

...remains to be seen whether 0.8 more bouts of satisfying sex is enough to win FDA approval. In the meantime, however, Boehringer Ingelheim insists that the results shore up evidence for the neurobiological basis for HSDD, such as in women like Wendy, who says, "I am not depressed. I love my husband. Most of the time we get along great. But after our second child was born, I just lost interest...

Author: /time Magazine | Title: Female Sexual Dysfunction: Myth or Malady? | 11/18/2009 | See Source »

...often before you realize that anything is wrong. To be effective, an antiviral cold drug would have to be taken as soon as you suspect you might be coming down with something. That's a tall order but not impossible. In the mid-1990s the German drug company Boehringer-Ingelheim developed an antiviral molecule, dubbed BIRR 4, that proved in clinical trials to significantly shorten most colds triggered by rhinoviruses and lessen their severity. The product worked by mimicking those molecular footholds used by rhinoviruses to gain entry into human cells. Spraying the nasal passages every few hours...

Author: /time Magazine | Title: How Come We Can't Cure The Cold? | 3/10/2003 | See Source »

...much by enlightened self-interest as by altruism, but the decision by five pharmaceutical giants to slash the price of AIDS drugs in Africa has the potential to be an important milestone in the battle against the killer disease. Bristol Myers Squibb, Glaxo Wellcome PLC, Merck and Co., Boehringer Ingelheim GmbH and Roche Holding AG are set Thursday to announce a program negotiated with the United Nations to cut the price of AIDS drugs by as much as 90 percent on a continent where more than 23 million people are infected with HIV. The business context for that decision...

Author: /time Magazine | Title: Why Africa Will Get AIDS Drugs at Giveaway Prices | 5/11/2000 | See Source »

Well, Stockholm isn't calling yet, but good news on the cold front was reported at a medical conference in Toronto last week. In preliminary tests sponsored by Boehringer Ingelheim Pharmaceuticals, an experimental compound with an ungainly moniker--BIRR 4--managed to cut the severity of cold symptoms in half without major side effects. The results were immediately hailed in the media as a breakthrough, although Dr. Ronald Turner, a pediatrician at the Medical University of South Carolina in Charleston who helped direct the research, was quick to add a dose of caveat. "We've got a ways...

Author: /time Magazine | Title: FOOL A COLD | 10/13/1997 | See Source »

| 1 |